文献速递肝病消化道肿瘤与早癌

2003-2021年美国全国真实世界肝硬化患者队列的特征与生存率更新

Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real-world U.S. patients, 2003-2021.
PubMed 文献 · Aliment Pharmacol Ther · 2024-05-01

该回顾性研究基于美国全国商业保险数据库,纳入628,743例肝硬化患者,分析病因分布、肝细胞癌(HCC)发病率与生存率随时间的变化。结果显示非酒精性脂肪性肝病(NAFLD)占45%,HCV占19.5%,酒精性肝病(ALD)占16.3%;2014-2021年队列较2003-2013年更老、失代偿更少但HCC和NAFLD更多,且生存更差(aHR 1.14)。

要点

  • 肝硬化病因以NAFLD(45%)为主,其次为HCV(19.5%)和ALD(16.3%)。
  • 非洲裔美国人失代偿率最高(60.6%),亚裔HCC率最高(2.4%)。
  • 2014-2021年队列生存较2003-2013年差(aHR 1.14,95%CI 1.08-1.20)。

核心结论

  • 肝硬化患者HCC发病率和生存率因病因不同而异,隐源性肝硬化生存率最低,且较近时期(2014-2021)生存率更低。

研究设计与样本

  • 回顾性研究,使用Optum去标识化Clinformatics® Data Mart数据库(CDM)中全国商业保险肝硬化患者样本,共纳入628,743例。

主要发现

  • 病因分布:NAFLD占45%,HCV占19.5%,ALD占16.3%。
  • 非洲裔美国人失代偿率最高(60.6%),亚裔HCC率最高(2.4%),均p < 0.001。
  • 非洲裔美国人更常见HCV(28.4%),西班牙裔/拉丁裔更常见NAFLD(49.2%),p < 0.001。
  • 2014-2021年队列较2003-2013年更老(63.0 ± 12.8岁 vs. 57.0 ± 14.3岁),失代偿更少(54.5% vs. 58.3%),但HCC更多(1.7% vs. 0.6%)、NAFLD更多(46.5% vs. 44.2%),均p < 0.001。
  • HCC总体年发病率为0.76%(95% CI: 0.75-0.77),5年累积发病率为4.03%(95% CI: 3.98-4.09);总体中位生存时间为11.4年(95% CI: 11.3-11.5),5年累积生存率为73.4%(95% CI: 73.3%-73.6%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adverse outcomes of cirrhosis remain a top priority. AIMS: We examined the distribution of cirrhosis causes, HCC incidence and mortality and related changes over time in a nationwide U.S. METHODS: A retrospective study of a national sample of commercially insured patients with cirrhosis from Optum's de-identified Clinformatics® Data Mart Database (CDM). RESULTS: A total of 628,743 cirrhosis cases were identified with 45% having NAFLD, 19.5% HCV, and 16.3% ALD. African Americans had the highest rate of decompensation (60.6%), while Asians had the highest rate of HCC (2.4%), both p < 0.001. African Americans more frequently had HCV (28.4%) while Hispanic/Latinos more frequently had NAFLD (49.2%, p < 0.001). Patients in the 2014-2021 cohort were significantly older (63.0 ± 12.8 vs. 57.0 ± 14.3), less frequently decompensated (54.5% vs. 58.3%) but more frequently had HCC (1.7% vs. 0.6%) and NAFLD (46.5% vs. 44.2%), all p < 0.001. The overall annual incidence of HCC was 0.76% (95% CI: 0.75-0.77) with a 5-year cumulative incidence of 4.03% (95% CI: 3.98-4.09), with significant variation by sex, race/ethnicity, and cirrhosis aetiology. The overall median years of survival were 11.4 (95% CI: 11.3-11.5) with a 5-year cumulative survival of 73.4% (95% CI: 73.3%-73.6%), also with significant disparities in similar subgroups (lowest in cryptogenic cirrhosis and worse in 2014-2021 vs. 2003-2013). The 2014-2021 period was independently associated with worse survival (aHR: 1.14, 95% CI: 1.08-1.20). CONCLUSIONS: HCC incidence and survival vary by aetiology among patients with cirrhosis, with cryptogenic cirrhosis having the lowest survival and lower survival in the more recent time period.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Tran S, Zou B, Lee K, et al. Updates in characteristics and survival rates of cirrhosis in a nationwide cohort of real-world U.S. patients, 2003-2021. Aliment Pharmacol Ther. 2024. PMID: 38693757. doi:10.1111/apt.18024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。